The observation in animal models is consistent with the clinical dataset analyses that poor outcomes in lung cancer patients with simultaneous high expression of ADAM9 and VEGFA or of ADAM9 and ANGPT2. This evidence concerns the gene VEGFA and lung carcinoma.